川宁生物：密切关注银发经济市场需求变化，已布局化妆品原料、保健品原料等领域的研发

Core Viewpoint - The company is actively responding to national policy directives aimed at enhancing the adaptability of consumer goods, particularly in the context of the aging population and the silver economy [1] Company Developments - The company has noted the implementation plan issued by six departments, including the Ministry of Industry and Information Technology, which emphasizes the need for the development and design of products catering to the elderly [1] - The company is leveraging its synthetic biology technology platform to develop products in the cosmetics and health supplement sectors, with successful industrial applications of products such as rosmarinic acid, 5-hydroxytryptophan, and ergothioneine [1] Financial Performance - For the period from January to September 2025, the company reported a revenue of 3.436 billion yuan, representing a year-on-year decline of 22.90% [1] - The company's net profit attributable to shareholders was 611 million yuan, reflecting a year-on-year decrease of 43.17% [1]